A review of the research progress of new antiviral drugs for chronic hepatitis B

Chronic hepatitis B (CHB) is a chronic progressive disease caused by hepatitis B virus (HBV).

Antiviral therapy is an important and effective method to treat CHB.

Since the first NAs antiviral drug came out in 1999, the pace of hepatitis B antiviral treatment has not stopped.

1

Virus entry inhibitor

Myrcludex B

It is a hepatitis B virus entry inhibitor independently developed by MYR Pharma.

2

Capsid inhibitor

Could Saidin (GLS4)

GLS4 is a new hepatitis B drug (class I) of core protein allosteric modulator independently developed by my country, developed by Guangdong Dongyang Sunshine Pharmaceutical Co.

The study included 250 patients with chronic HBV infection, divided into 125 people in the initial treatment group (patients who have not been treated or who have not been exposed to anti-HBV drugs in the last 6 months) and 125 people in the treated group (taking entecavir for more than 1 year, HBV DNA <50 IU/mL).

Compared with baseline, in the initial treatment cohort, the mean HBV DNA decline in the combined treatment group was 6.

In the treated cohort, compared with baseline, the mean reduction of HBV pgRNA in the combination treatment group and the entecavir single-agent group were 1.

GLS4/RTV combined with Entecavir has good safety and tolerability.

3

Nucleic acid interference drugs or other nucleic acid drugs

ARO-HBV (JNJ3989)

ARO-HBV (JNJ3989) is a nucleic acid interference drug developed by Arrowhead.

In addition, the nucleic acid interference varieties currently under research include AB729, VIR-2218, RG6346, SR016, STSG-002, BB-103, etc.

4

Immunomodulator

Vesatolimod (GS-9620)

The main targets of immunomodulators currently under research (except vaccines) are TLR7, TLR8, PD-L1 and PD-1.

For the TLR7 target, Gilead has developed Vesatolimod (GS-9620).

In short, although antiviral therapy has gone through nearly 20 years, the evidence of clinical research is increasing, the drug has strong efficacy and small adverse reactions, but there are still some problems that need to be resolved and need further research.

Finally, let us look forward to the development and marketing of more antiviral drugs in the future to benefit patients.

Reference source:

1.

2.
Seto, Wai-Kay, Ying-Ru Lo, Jean-Michel Pawlotsky, and Man-Fung Yuen.
Chronic hepatitis B virus infection [J].
The Lancet.
2018, 392 (10161): 2313-24.

3.
EASL2020: SAT452.

4.
Kitamura K, Que L, Shimadu M, et al.
Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus[J].
PLoS Pathog, 2018, 14(6): e1007124.
DOI: 10.
1371/journal.
ppat .
1007124.

5.
Fanning et al.
, (2019).
Therapeutic strategies for hepatitis B virus infection: towards a cure.
Nature Reviews Drug Discovery.